KO is 15-20% above its own five-year P/E premium band at current 27.6x multiple

• Five-year average P/E: roughly 23-25x
• Current P/E: 27.6x
• PEG: 4.39 (vs. 2.0x target for multi-decade compounding)
• 88% five-year return means 'everyone who wanted to own that quality already did'

↩ rebuts: “Premium multiple is justified by 42.1% ROE and 34.9% operating margins”

Q2 2026's +17% EPS is optical, not operational—driven by financial engineering

• Tax rate: ~18.9% (vs ~21% prior year)
• Interest expense: fell from $445M to $369M as KO paid down debt
• Organic EPS growth (stripping financial engineering): 6-9%
• Q3 2025 revenue: +0.6% YoY
• Q4 2025 revenue: negative on reported basis (impaired)

↩ rebuts: “Earnings accelerating toward sustainable higher growth”

Q2 2026 revenue likely included pull-forward shipments ahead of tariffs and front-loaded bottler inventory

• One quarter does not a trend make
• Quarterly revenue is 'choppy'

Technical setup signals statistically rare event that historically resolves via mean reversion

• Price $91.99 above upper Bollinger Band of $91.47
• RSI: 73.18
• MACD histogram: +0.33 (modest, not expanding)
• July 28 gap-up volume: 34.98M
• Aug 24 volume: 14.75M (dried up, below average)
• ATR: $1.60

↩ rebuts: “Trend-following signals support buying the rally”

Downside targets: $88.10-88.30 (first BOLL mid/VWMA cluster, ~4% give-back), $84.49 (50 SMA, ~8% drop), $77 zone (200 SMA, ~16% reset)

• Reasonable downside targets stated
• Stop for tactical buyer: ~$89
• Stop for strategic buyer: ~$84
• 2.6% to 8.1% downside risk before bull case re-engages

Capital return story is underwhelming—management signaling stock isn't cheap via preference for debt paydown over buybacks

• Buyback yield (TTM): 0.23% ($0.9B / $395B market cap)
• Dividend yield: 2.33%
• Combined yield: ~2.56%
• Net debt: $30.6B
• TTM buyback: $0.9B (described as 'rounding error' on $48B revenue base)
• 'When a CEO thinks their stock is cheap, they buy it back aggressively'

↩ rebuts: “Capital return compound (dividend + buyback) is 'a yield plus growth plus capital return compound that prints money'”

Berkshire Hathaway has been trimming KO by ~25% over a multi-year period—not a vote of confidence

• Berkshire trim: ~25% over multi-year period
• Trajectory: distribution, not accumulation
• 'If Buffett's heirs thought KO at $91.99 was a screaming buy, they'd be adding, not signaling "we'll just hold what we have"'

↩ rebuts: “Berkshire CEO Greg Abel said Berkshire 'won't sell KO'”

Full-calorie CSD volumes declining structurally in developed markets; unit volume negative

• Full-calorie CSD volumes declining for over a decade in developed markets
• KO growth from pricing, not units
• 'Per Yahoo Finance: Olipop is beating Big Soda'

↩ rebuts: “Fairlife, BodyArmor, Costa Coffee represent successful portfolio diversification”

New-age beverage competitors (OLIPOP, Poppi, Celsius, Liquid Death, Ghost, Bloom) taking share from KO every quarter

• Fairlife revenue: ~$1.5-2B against KO ~$48B base (~3-4%)
• Dairy protein and functional beverages growing 25-50% annually at competitors like CELH
• KO's organic growth in those categories is 'far slower'

GLP-1 volume impact hasn't fully shown yet; Wegovy, Zepbound, Mounjaro scripts accelerating

• Q2 reported before broader GLP-1 wave hit full adoption
• 'By Q3 2026 reporting, KO will be running up against tougher comparable reads with GLP-1s increasingly suppressing discretionary calories'

↩ rebuts: “GLP-1 health trend thesis is 'weakest' argument”

PepsiCo (PEP) is the relevant competitor in growth markets, growing EM beverage and snack categories faster

• KO's international business is 'more mature—slower growth in established markets'
• PEP retained bottling assets; KO refranchised bottlers
• 'In a beverage category shift, the integrated model can pivot faster'

↩ rebuts: “PEP's $40B international business dismissed as 'Goliath vs. David'”

Multiple compression will drive bear case even if DCF assumptions are correct—27.6x P/E sits at top of revaluation range that will compress 10-15% when 'normalization' hits

• If growth reverts to 4-5% historical trajectory, 27.6x P/E is 'at the top of a revaluation range'
• Multiple compression: 10-15% when next quarter's 'normalization' hits

↩ rebuts: “DCF assumptions are 'wrong' and don't reflect go-forward performance”

FX headwinds from ~65% international revenue not yet fully reflected; hedges roll off over next 12-24 months

• ~65% international revenue
• DXY strength = translation hit
• KO hedges 12-24 months forward but 'hedges roll off'

↩ rebuts: “Higher-for-longer rates 'help' KO via bond-proxy trade”

Asymmetric risk profile: Upside to fair value 8-12% vs. downside to mean reversion 10-15% vs. downside to category shock 15-20%

• Upside to fair value (DCF-adjusted): 8-12% over 12 months if everything goes right
• Downside to mean reversion: 10-15% if growth normalizes or multiples compress
• Downside to real category shock (GLP-1 acceleration, share loss, FX): 15-20%